Fungal Tech Success Upends Deal, Spurs Biotech Pivot for Mushrooms Inc.

ESTERO, FL – March 24, 2026 – In a dramatic strategic reversal, biotech firm Mushrooms Inc. (OTC: MSRM) has paused a planned corporate transaction following a significant research and development breakthrough. The company today announced it has achieved a successful early-stage proof of concept for its novel infection-detection technology, a development that has prompted a full-scale reassessment of its merger with logistics firm SecurCapital Corp.

The announcement signals a major pivot for the company, shifting its focus squarely back to its proprietary fungal biotechnology platform, MycoLabX, just as it was preparing to be absorbed into a logistics-focused entity. This move underscores the rapidly increasing value of mycelium-based technologies in a market hungry for sustainable and intelligent biomaterials.

A Breakthrough in Wound Care

At the heart of the company’s strategic shift is a milestone achieved by its MycoLabX platform. According to the company, prototype testing has successfully demonstrated that its proprietary mycelium-based films produce a visible color-change when exposed to bacterial activity. This confirms the core sensing mechanism for a new class of 'smart' biomaterials designed to detect infections.

This early-stage validation is a critical step forward for the technology, which is detailed in a non-provisional patent application filed in late 2023. The patent, titled "METHOD OF GENERATING MULTIFUNCTIONAL MYCELIUM PRODUCTS," outlines a method for using mycelium not only for bacterial detection but also for potential nutrient delivery, suggesting a dual-function approach to advanced wound care.

The potential application in medical settings is significant. The global biomaterial wound dressing market was valued at over $7.7 billion in 2026 and is projected to exceed $11 billion by 2031, driven by an aging population and a rising incidence of chronic wounds like diabetic ulcers. A dressing that could provide a clear, visual indication of an emerging infection without being removed could revolutionize patient monitoring, reduce healthcare costs, and improve outcomes by enabling earlier intervention.

While the company has labeled the achievement an "early-stage proof of concept," it is moving quickly to build on the momentum. Mushrooms Inc. is now preparing for an expanded phase of development that includes more rigorous testing and third-party validation, with plans to engage leading U.S. research and defense-related institutions.

An AI-Powered Fungal Ecosystem

Bolstering the biomaterial breakthrough is the successful completion of beta testing for MycoLab.ai, the company's proprietary artificial intelligence platform. Described as a structured research environment focused exclusively on mycology—the study of fungi—the platform is designed to streamline the discovery and analysis of fungal science.

By using AI to organize and parse vast amounts of foundational scientific data, MycoLab.ai aims to accelerate the application of mycological research for product developers, scientists, and growers. This positions the platform in a burgeoning field where AI is increasingly used to unlock biological insights. While competitors are using AI for specific tasks like species identification or drug discovery, Mushrooms Inc. is aiming to create a comprehensive data ecosystem to support its entire innovation pipeline.

The company believes this integrated approach, combining the MycoLabX biomaterials initiative with the MycoLab.ai data engine, creates a powerful, scalable ecosystem for rapid product development and commercialization across sectors including healthcare, sustainable materials, and agriculture.

From Partnership to Power Play

The technological advancements have had immediate and profound business implications, leading to the re-evaluation of a deal that would have fundamentally changed the company. On January 29, 2026, Mushrooms Inc. announced a Share Exchange Agreement to acquire SecurCapital Corp., a supply chain and logistics provider. The original plan involved Mushrooms Inc. rebranding as "SecurCapital Corp.," installing SecurCapital's CEO Stephen Russell as its new chief executive, and, most notably, separating its legacy biotechnology assets—the MycoLabX business—from the publicly traded company.

Market reaction to the initial announcement was negative, with the company's stock declining 20% on the day of the news, suggesting investor apprehension about the shift away from biotechnology. Now, with its core technology demonstrating significant potential, Mushrooms Inc. has reversed course.

In its latest announcement, the company stated that the recent milestones have "materially strengthened the company’s standalone position and strategic flexibility." Both Mushrooms Inc. and SecurCapital have mutually agreed that the original transaction structure is being re-evaluated. This turn of events suggests the MycoLabX platform is no longer considered a "legacy asset" to be spun off, but rather the central pillar of the company's future value.

Navigating a New Trajectory

Freed from the constraints of the previous agreement, Mushrooms Inc. is charting a new course directly into the heart of the booming bio-economy. The company is now actively evaluating strategic funding opportunities to accelerate the validation and commercialization of its MycoLabX platform. This move comes at an opportune time, as investor interest in fungal biotechnology and sustainable biomaterials is surging.

The broader biomaterials market is projected to grow from over $170 billion in 2024 to more than $500 billion by 2034. Venture capital is flowing into the sector, with specialized firms like The Fungi VC emerging and startups like Mycocycle and Hexagon Bio securing multi-million dollar funding rounds for their fungus-based innovations.

Mushrooms Inc. is now positioning itself to capture a piece of this market, seeking accredited investors to participate in its next growth phase. The capital would be used to scale up biomaterials production and advance the technology toward clinical and institutional validation. While the company noted its constructive relationship with SecurCapital and left the door open for future collaboration, its immediate focus has clearly shifted. With its core technology now at the forefront, Mushrooms Inc. is betting its future not on a corporate merger, but on the vast, untapped potential of the fungal kingdom.